A carregar...
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
BACKGROUND: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC. CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation e...
Na minha lista:
| Publicado no: | Gynecol Oncol Rep |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6014583/ https://ncbi.nlm.nih.gov/pubmed/29946554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2018.05.011 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|